Activist Beretta Escalates Fight After Board Rejects Tender Offer Waiver, Threatens Litigation
RGR sits 50% above its 52-week low of $28.33.
Summary
Activist investor Beretta Holding S.A. expressed deep dismay and threatened litigation after Sturm, Ruger & Co.'s Board rejected its request for a poison pill waiver, obstructing a premium tender offer.
Key Events · Ownership and Investor Activity · RGR
-
Board Rejects Poison Pill Waiver
Sturm, Ruger & Co.'s Board denied Beretta Holding S.A.'s request for an exemption from its poison pill rights plan, preventing the proposed tender offer for an additional 20.05% of shares.
-
Premium Tender Offer Blocked
The Board's decision effectively obstructs Beretta's all-cash tender offer at $44.80 per share, which represented a significant premium of approximately 20% to the 60-day volume-weighted average price.
-
Litigation Threat Issued
Beretta Holding S.A. expressed deep dismay at the Board's action and announced it is actively assessing all litigation options against the Board and its members.
-
Meeting Scheduled Amidst Conflict
An in-person meeting between Beretta Holding S.A. and Sturm, Ruger & Co. has been arranged for April 9, 2026, following the Board's rejection and Beretta's expressed skepticism regarding engagement sincerity.
Analysis · RGR · Manufacturing
This filing marks a significant escalation in the ongoing activist campaign by Beretta Holding S.A. against Sturm, Ruger & Co. The Board's rejection of the poison pill waiver directly blocks Beretta's proposed all-cash tender offer at a substantial premium, indicating a firm stance against the acquisition attempt. Beretta's immediate threat of litigation signals a prolonged and potentially costly battle for control, creating uncertainty for shareholders. The upcoming meeting on April 9, 2026, will be critical to watch for any potential de-escalation or further entrenchment of positions.
At the time of this filing, RGR was trading at $42.38 on NYSE in the Manufacturing sector, with a market capitalization of approximately $638.1M. The 52-week trading range was $28.33 to $48.21. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.